- Home
- BIIB vs ADM Comparison
BIIB vs ADM Comparison
Compare BIIB & ADM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ADM
- Stock Information
- Founded
- BIIB 1978
- ADM 1902
- Country
- BIIB United States
- ADM United States
- Employees
- BIIB N/A
- ADM N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ADM Packaged Foods
- Sector
- BIIB Health Care
- ADM Consumer Staples
- Exchange
- BIIB Nasdaq
- ADM Nasdaq
- Market Cap
- BIIB 25.1B
- ADM 26.1B
- IPO Year
- BIIB 1991
- ADM N/A
- Fundamental
- Price
- BIIB $160.85
- ADM $53.20
- Analyst Decision
- BIIB Buy
- ADM Hold
- Analyst Count
- BIIB 25
- ADM 12
- Target Price
- BIIB $258.57
- ADM $62.92
- AVG Volume (30 Days)
- BIIB 1.7M
- ADM 3.4M
- Earning Date
- BIIB 10-30-2024
- ADM 11-18-2024
- Dividend Yield
- BIIB N/A
- ADM 3.76%
- EPS Growth
- BIIB 10.05
- ADM N/A
- EPS
- BIIB 11.06
- ADM 3.56
- Revenue
- BIIB $9,607,500,000.00
- ADM $87,010,000,000.00
- Revenue This Year
- BIIB N/A
- ADM N/A
- Revenue Next Year
- BIIB N/A
- ADM $2.56
- P/E Ratio
- BIIB $14.54
- ADM $14.95
- Revenue Growth
- BIIB N/A
- ADM N/A
- 52 Week Low
- BIIB $153.62
- ADM $48.92
- 52 Week High
- BIIB $268.30
- ADM $77.35
- Technical
- Relative Strength Index (RSI)
- BIIB 37.71
- ADM 43.83
- Support Level
- BIIB $158.44
- ADM $52.52
- Resistance Level
- BIIB $165.29
- ADM $54.76
- Average True Range (ATR)
- BIIB 4.09
- ADM 1.07
- MACD
- BIIB 1.04
- ADM 0.31
- Stochastic Oscillator
- BIIB 32.51
- ADM 58.84
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ADM Archer-Daniels-Midland Company
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.